Researchers from the University of Milan and collaborators reported the discovery and preclinical profile of a first-in-class covalent PFKFB3 inhibitor designed to achieve durable and selective suppression of tumor glycolysis while potentially improving tolerability compared with nonselective or reversible glycolysis inhibitors.
Innovent Biologics Co. Ltd.’s Claudin18.2-targeted antibody-drug conjugate (ADC), arcotatug tavatecan (IBI-343, TAK-921), met the primary endpoint in the international multicenter phase III G-Hope-001 trial in advanced gastric cancer, according to interim results.
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s biotechnology sector, it was that the industry’s center of gravity is shifting. While Chinese companies once relied heavily on PD-1 antibodies and licensing deals to gain international visibility, this year’s oral presentations showcased a broader innovation base.
Agios Pharmaceuticals Inc.’s potential $665 million deal for Oscotec Inc.’s cevidoplenib, a phase III-ready oral SYK inhibitor to treat immune thrombocytopenia, marks a new chapter of development focused on cancer therapy resistance for Oscotec, CEO Yoon Tae-young said.
China’s National Medical Products Administration (NMPA) on June 4 granted conditional approvals to two oncology drugs from Lupeng Pharmaceutical Co. Ltd. and Vcare Pharmatech Co. Ltd., as well as one hemophilia drug developed by Staidson Biopharmaceutical Co. Ltd.
Japan has granted marketing approval to Oncolys Biopharma Inc.’s oncolytic adenovirus product, Telomelysin (suratadenoturev, OBP-301), for treating esophageal cancer in patients who are not eligible for curative resection or chemoradiotherapy. The approval marks the first oncolytic adenovirus product approved for esophageal cancer.
Ahead of an approval bid with its own candidate in non-small-cell lung cancer, GSK plc is planting a stake in the space by way of the $10.6 billion buyout of Nuvalent Inc. for $124 per share, a 40% premium to Nuvalent’s last closing price and a 26% premium to the 30-calendar day amount. Net of cash acquired, GSK’s investment will total about $9.4 billion.
Pheon Therapeutics Ltd. has patented antibody-drug conjugates, comprising an antibody targeting CDCP1 covalently linked to a cytotoxic drug through a linker, that are potentially useful for the treatment of cancer.
Scientists from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified bicyclic tetrahydrothiazepine derivatives acting as diacylglycerol kinase α (DGKA) and/or diacylglycerol kinase ζ (DGKZ) inhibitors reported to be potentially useful for the treatment of cancer.
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. has divulged tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or PTPN2 inhibitors that are potentially useful for the treatment of cancer.
RSS
